Eli Lilly price target lowered to $1,190 from $1,250 at Citi
Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...
Medscape17h
Women Researchers Remain Underrepresented in Pharma-Sponsored IBD Presentations
Study urges industry to be more transparent and fairer in selecting speakers, and to recruit more women to steering ...
Hosted on MSN13h
Amgen price target lowered to $295 from $310 at Citi
Citi lowered the firm’s price target on Amgen (AMGN) to $295 from $310 and keeps a Neutral rating on the shares. Ahead of the ...
Hosted on MSN18h
Novo Nordisk shares surge on results of new obesity drug trial
Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...
IPWatchdog9h
The Growing Market for Weight Loss Treatments: Innovation, Patents, and the Future of GLP-1 Agonists
In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...
Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
Trump order set to halt supply of HIV, malaria drugs to poor countries, sources say
The Trump administration has moved to stop the supply of lifesaving drugs for HIV, malaria and tuberculosis, as well as ...